Related Experiment Video

Updated: Jul 18, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven

Yutian Wang1, Timothy Wiltshire, Jamie Senft

  • 1Mary Babb Randolph Cancer Center, West Virginia University, 1835 Health Sciences South, P.O. Box 9300, Morgantown, WV 26506, USA. wwang@hsc.wvu.edu

Molecular Cancer Therapeutics
|December 19, 2006
PubMed

Insights

Irofulven causes DNA damage, activating the Fanconi anemia-BRCA pathway. FANCD2 plays a key role in cellular response and chemosensitivity to this anticancer agent.

Area of Science:

  • Oncology
  • Molecular Biology
  • DNA Repair

Background:

  • Fanconi anemia-BRCA pathway proteins are crucial for DNA damage response and frequently altered in cancer.
  • Irofulven, an illudin analogue, is a promising anticancer agent with incompletely understood DNA damage mechanisms.
  • Previous work showed irofulven activates ATM and downstream targets, indicating DNA damage induction.

Purpose of the Study:

  • To investigate if irofulven induces DNA double-strand breaks.
  • To determine the role of FANCD2 in cellular response and chemosensitivity to irofulven.
  • To elucidate the involvement of ATR and ATM in irofulven-induced DNA damage signaling.

Main Methods:

  • Utilized cell lines proficient or deficient for FANCD2, ATR, or ATM.
  • Assessed irofulven-induced FANCD2 monoubiquitination and nuclear foci formation.
  • Evaluated chromosome integrity and chemosensitivity in response to irofulven treatment.

Main Results:

  • Irofulven treatment led to FANCD2 monoubiquitination and nuclear foci formation.
  • ATR was identified as critical for mediating irofulven-induced FANCD2 monoubiquitination.
  • FANCD2 deficiency impaired chromosome integrity and altered chemosensitivity to irofulven.

Conclusions:

  • Irofulven induces DNA double-strand breaks and relies on FANCD2 for response.
  • ATR is essential for the irofulven-induced DNA damage response pathway involving FANCD2.
  • Targeting irofulven therapy to cancers with defects in the Fanconi anemia-BRCA pathway may hold clinical significance.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...